pep2-SVKE

Discontinued Product

pep2-SVKE (Cat. No. 1598) has been withdrawn from sale for commercial reasons.
Description: Inactive control peptide for pep2-SVKI (Cat. No. 1597)
Datasheet
Citations (1)
Reviews
Literature (4)

Biological Activity for pep2-SVKE

Inactive control peptide analog of pep2-SVKI, an inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluA2 AMPA receptor subunit.

Active Analog also available.

Technical Data for pep2-SVKE

M. Wt 1300.43
Formula C59H89N13O20
Sequence YNVYGIESVKE
Storage Desiccate at -20°C
CAS Number 1315378-76-7
PubChem ID 90479808
InChI Key AHURAWWDQDDHNP-OIKDQGPWSA-N
Smiles [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for pep2-SVKE

References are publications that support the biological activity of the product.

Collingridge and Isaac (2003) Functional roles of protein interactions with AMPA and kainate receptors. Neurosci.Res. 47 3 PMID: 12941441

Daw et al (2000) PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses. Neuron 28 873 PMID: 11163273

Kim et al (2001) Interaction of the AMPA receptor subunit GluR2/3 with PDZ domains regulates hippocampal long-term depression. Proc.Natl.Acad.Sci.U.S.A. 98 11725 PMID: 11573007

Li et al (1999) AMPA receptor-PDZ interactions in facilitation of spinal sensory synapses. Nat.Neurosci. 2 972 PMID: 10526335

View Related Products by Target

Keywords: pep2-SVKE, pep2-SVKE supplier, Inactive, control, peptide, 1597, Glutamate, AMPA, Receptors, iGlur, Ionotropic, 1598, Tocris Bioscience

1 Citation for pep2-SVKE

Citations are publications that use Tocris products. Selected citations for pep2-SVKE include:

Dickinson et al (2009) A novel mechanism of hippocampal LTD involving muscarinic receptor-triggered interactions between AMPARs, GRIP and liprin-alpha. Mol Brain 2 18 PMID: 19534762


Reviews for pep2-SVKE

There are currently no reviews for this product. Be the first to review pep2-SVKE and earn rewards!

Have you used pep2-SVKE?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.